CURRICULUM VITAE Gerald Louis Andriole, Jr., M.D. Address ...

65. Andriole, G.L. and Civitelli, K.: Prolonged Biochemical Response to Combined Androgen Receptor
Blockade and 5-α Reductase Inhibition for Patients with Biochemical Relapse After Definitive Therapy
for Early Stage Prostate Cancer. Innovators in Urology, February, 1998. Prostate Cancer and Prostatic
Diseases (1998) 1, Suppl 1, S17.
66. Bonilla, J., Hudson, P.B., Bruskewitz, R., Fuselier, H.A., Rosenblatt, S., Harrison, L.H., Malek, G.H.,
Schellhammer, P.F., Matsumoto, A., Walsh, P.C., Resnick, M., Roy, J.B., McConnell, J., Andriole, G.L.,
Best, S., and Taylor, A.M.: The Effect of Finasteride on the Natural Progression of Increasing Prostate
Volume Over Time. European Association of Urology Congress, Barcelona, Spain, March, 1998.
67. Chhikara, S., Klutke, C.G. and Andriole, G.L.: Long Term Follow-Up of Antegrade Collagen Injection
for Post Radical Prostatectomy Stress Urinary Incontinence. 93 rd Annual Meeting of the American
Urological Association, San Diego, CA, May, 1998.
68. Andriole, G.L., Walsh, P.C., Epstein J.I., Hudson P., Romas, N., Cook, T.J., Waldstreicher, J., Guess,
H.: Treatment with Finasteride Preserves the Usefulness of PSA in Prostate Cancer Detection. 93 rd
Annual Meeting of the American Urological Association, San Diego, CA, May, 1998.
69. McConnell, J., Malek, G., Bruskewitz, R., Hudson, P., Geller, J ., Albertsen, P., Saltzman, B., Walsh,
P.C., Andriole, G.L., Wang, D., Waldstreicher, J.: Acute Urinary Retention and BPH-Related Surgery:
Predicting Those at Highest Risk and Prevention with Finasteride. 93 rd Annual Meeting of the American
Urological Association, San Diego, CA, May, 1998.
70. Fowler, J.E., Gottesman, J.E., Bardot, S.F., Reid, C.F., Andriole, G.L., Bernhard, P.H., Rivera-Ramirez,
I., Libertino, J.A., and Soloway, M.S.: A Phase I/III Dose Ranging Study of DUROS (Leuprolide)
Implantable Therapeutic System in Patients with Advanced Prostate Cancer. 93 rd Annual Meeting of the
American Urological Association, San Diego, CA, May, 1998.
71. Naughton, C.K., Smith, D.S., and Andriole, G.L.,: Does Nerve-Sparing Radical Cystoprostatectomy
Compromise Tumor Control? Annual Meeting of the South Central Section of the American Urological
Association, Cancun, Mexico, January, 1999.
72. Levin, D.L., Gelmann, E.P., Andriole, G.L., Chia, D., Crawford, E.D.: Free and Total PSA in 7,183
Pilot Study Participants in the PLCO Screening Trial. 94 th Annual Meeting of the American Urological
Association, Dallas, TX, May, 1999.
73. Fowler, J.E., Gottesman, J.E., Bardot, S.F., Reid, C.F., Andriole, G.L., Bernhard, P.H., Rivera-Ramirez,
I., Libertino, J.A., Soloway, M.S.: Duros Leuprolide Implantable Therapeutic Systems in Patients with
Advanced Prostate Cancer: 14 Month Results of a Phase I/II Dose-Ranging Study. 94 th Annual Meeting
of the American Urological Association, Dallas, TX, May, 1999.
74. Andriole GL, Fowler J, Feldman R, Gittelman M, Gleason D, Klimberg I, Morton J, Harris R, Aronson
W, Fitch W, Gottesman J, Rivera-Ramirez I, Marks L, Sharifi R, Wiatrak O, Tully N, Bardot S, Reid F,
and Soloway M: A Phase III Efficacy and Safety Study of DUROS Leuprolide Implantable
Therapeutic Systems in Patients with Prostate Cancer. Abstract #1288, Annual Meeting of the American
Society of Clinical Oncology, Atlanta GA, May, 1999
75. Diaz, N.A., Yan, Y., Kibel, A.S., Li, B.D., Vollmer, R., Hudson, M.A., Humphrey, P.A., Swanson, P.E.,
Andriole, G.L.: Prognostic Significance of p53, Ki-67, EGFR, c-erbB-2, and bcl-2 for First Recurrence
of Bladder Cancer. 95 th Annual Meeting of the American Urological Association, Atlanta, GA, April-
May, 2000.
16